[
  {
    "pmid": "MOCK_PM_90000001",
    "source": "pubmed",
    "title": "Empagliflozin and eGFR Slope in Macroalbuminuric Type 2 Diabetes: A Randomized Trial",
    "abstract": "In a 24-month randomized controlled trial of patients with T2DM and macroalbuminuria (UACR >300), empagliflozin 10 mg reduced annual eGFR slope and lowered the composite of major adverse kidney events compared with placebo. Hyperkalemia was rare. Findings align with KDIGO 2024 guideline recommendations.",
    "journal": "Synthetic Journal of Nephrology",
    "jif": 12.5,
    "days_since_pub": 3
  },
  {
    "pmid": "MOCK_PM_90000002",
    "source": "pubmed",
    "title": "Finerenone in Normoalbuminuric DKD: Post Hoc Analysis of a Phase 3 Trial",
    "abstract": "Among normoalbuminuric patients with type 2 diabetes and eGFR 25-60, finerenone reduced UACR but had only modest effect on eGFR slope. Hyperkalemia incidence was 2.3 times higher than placebo. Authors discuss applicability to KDIGO and KDA guideline updates.",
    "journal": "Synthetic Endocrine Reports",
    "jif": 9.8,
    "days_since_pub": 5
  },
  {
    "pmid": "MOCK_PM_90000003",
    "source": "pubmed",
    "title": "Tirzepatide and Albuminuria Reduction in Advanced CKD: A Sub-Study",
    "abstract": "This sub-study of a dual GIP/GLP-1 agonist program enrolled patients with eGFR <30 and overt albuminuria. Tirzepatide reduced UACR by 38% versus placebo over 52 weeks. Severe hypoglycemia was rare. Effect on MAKE was a secondary endpoint.",
    "journal": "Synthetic Diabetes Care",
    "jif": 15.1,
    "days_since_pub": 2
  },
  {
    "pmid": "MOCK_PM_90000004",
    "source": "pubmed",
    "title": "Semaglutide vs Dulaglutide in Type 1 Diabetes with Diabetic Kidney Disease",
    "abstract": "Off-label comparison of two GLP-1 receptor agonists in T1DM-DKD demonstrated similar UACR reduction but a numerically lower all-cause mortality signal with semaglutide. Sample size limits inference.",
    "journal": "Synthetic Renal Medicine",
    "jif": 6.4,
    "days_since_pub": 8
  },
  {
    "pmid": "MOCK_PM_90000005",
    "source": "pubmed",
    "title": "Dapagliflozin and Hyperkalemia Risk in DKD: A Pharmacovigilance Cohort",
    "abstract": "Real-world cohort of 18,000 patients with T2DM-DKD found dapagliflozin associated with a 22% relative reduction in hyperkalemia compared with non-SGLT2 users. eGFR slope was preserved. No new safety signals.",
    "journal": "Synthetic Pharmacoepidemiology",
    "jif": 4.7,
    "days_since_pub": 11
  },
  {
    "pmid": "MOCK_PM_90000006",
    "source": "pubmed",
    "title": "Esaxerenone Add-on to SGLT2 Inhibitor in T2DM-DKD: A Pilot RCT",
    "abstract": "Pilot 24-week RCT of esaxerenone added to canagliflozin showed additional UACR reduction of 27% vs SGLT2i alone, with manageable potassium elevation. eGFR slope did not differ. Authors flag dose adjustment per KDIGO advice.",
    "journal": "Synthetic Hypertension Research",
    "jif": 5.2,
    "days_since_pub": 6
  },
  {
    "pmid": "MOCK_PM_90000007",
    "source": "pubmed",
    "title": "Retatrutide-Induced Weight Loss and Kidney Function: An Exploratory Analysis",
    "abstract": "Exploratory analysis of a triple agonist trial in T2DM patients with macroalbuminuria. Retatrutide 12 mg yielded marked weight loss but eGFR slope was non-inferior to placebo. UACR change was favorable but underpowered.",
    "journal": "Synthetic Obesity & Metabolism",
    "jif": 8.0,
    "days_since_pub": 4
  },
  {
    "pmid": "MOCK_PM_90000008",
    "source": "pubmed",
    "title": "All-Cause Mortality with Combination SGLT2i + Finerenone in Advanced CKD",
    "abstract": "Patient-level meta-analysis (n=11,200) of T2DM-DKD with eGFR <30 found a 14% reduction in all-cause death with combined empagliflozin + finerenone vs either alone. Hyperkalemia not increased. Consistent with KDIGO 2024 hierarchical therapy.",
    "journal": "Synthetic Lancet Diabetes",
    "jif": 18.9,
    "days_since_pub": 1
  },
  {
    "pmid": "MOCK_PM_90000009",
    "source": "pubmed",
    "title": "Liraglutide and Albuminuria in Korean Adults with T2DM: KDA Cohort",
    "abstract": "KDA registry analysis of 4,300 Korean adults with T2DM and microalbuminuria. Liraglutide associated with 18% UACR reduction at 12 months. Severe hypoglycemia infrequent. Authors note alignment with Korean Diabetes Association 2025 statement.",
    "journal": "Synthetic Korean Endocrine Journal",
    "jif": 3.1,
    "days_since_pub": 14
  },
  {
    "pmid": "MOCK_PM_90000010",
    "source": "pubmed",
    "title": "A Narrative Review of Cardiometabolic Drugs in Aging",
    "abstract": "This non-systematic narrative review covers diet, exercise, and broad metabolic concepts. No specific kidney outcomes or DKD drug analyses are presented.",
    "journal": "Synthetic Geriatric Bulletin",
    "jif": 1.2,
    "days_since_pub": 25
  }
]